This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 20 No. 2, August 2008
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Schiff, D.
PubMed
Right arrow Articles by Schiff, D.

AAP Grand Rounds 20:20-21 (2008)
© 2008 American Academy of Pediatrics

SENIOR MEMBERS/INFECTIOUS DISEASES

Pertussis Immunization of the Newborn

Source: Knuf M, Schmitt H-J, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr. 2008;152(5):655–660; doi:10.1016/j.jpeds.2007.09.034[CrossRef][Medline]

The first 20% of the full text of this article appears below.


PICO

Question: Among healthy newborns does immunization with acellular pertussis accelerate vaccine-induced immunity (or immunologic tolerance) against pertussis?

Question type: Intervention

Study design: Prospective, double-blind, controlled trial

 

To assess the effect on subsequent immunity resulting from pertussis immunization in newborns, investigators from the Children’s Hospital, Mainz, Germany; GlaxoSmithKline Biologicals; and the University of Geneva, Switzerland, conducted a double-blinded, randomized control trial in healthy neonates vaccinated during the first week of life.

Study infants were born after an uncomplicated 36- to 42-week pregnancy with a birth weight ≥2,500 grams and a 5-minute Apgar ≥7. Infants were randomized to receive one dose of either trivalent acellular pertussis (aP) vaccine or hepatitis B (HBV) vaccine at 2–5 days of age. Subsequently, all infants received vaccination with DTaP-HBV-IPV/Hib at two, four, and six months of age.

Overall, 121 neonates were enrolled in the study; 60 . . . [Full Text of this Article]

Donald Schiff, MD, FAAP
General Academic Pediatrics, University of Colorado School of Medicine and The Children’s Hospital, Aurora, Colorado